Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months

Clinical Neuropharmacology

Volumn 24, Issue 1, 2001, Pages 31-42

  Thomas, Astrid ^a   Iacono, Diego ^a   Bonanni, Laura ^a   D'Andreamatteo, Giordano ^a   Onofrj, Marco ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Servizio di Neurofisiopatologia   (Italy)

Author keywords

Alzheimer's disease; Donepezil; Event related potential; Rivastigmine; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVENT RELATED POTENTIAL; FEMALE; HUMAN; INTELLIGENCE TEST; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; EVENT-RELATED POTENTIALS, P300; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; PHENYLCARBAMATES; PIPERIDINES; VITAMIN E;

EID: 0035114107     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200101000-00007     Document Type: Article

References (42)

1. Neurotrasmitter deficits in Alzheimer's disease and in other dementing disorders
2. The cholinergic hypothesis of Alzheimer's disease: A review of progress
3. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer disease: The Tacrine Study Group
4. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase
5. New therapeutic approaches to Alzheimer's disease
6. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
7. Donepezil
8. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease
9. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controoled trial
10. Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality: The Tacrine Study Group
11. A 24-week, double-blind, placebo-controlled trail of Donepezil in patients with Alzheimer's disease
12. Cholinesterase inhibitors: A new class of psychotropic compounds
13. A new rating scale for Alzheimer's Disease
14. Clinical utility of long latency "cognitive" event-related potentials (P300): The cons
15. Clinical utility of long latency "cognitive" event-related potentials (P300): The pros
16. Meta-analysis of P300 normative aging studies
17. Auditory long latency eventrelated potentials in Alzheimer's disease and multiinfarct dementia
18. P300 assessment of early Alzheimer disease
19. Mapping of event-related potentials (ERPs) to auditory and visual odd-ball paradigms in patients affected by different forms of dementia
20. Electrophysiologic differences between subtypes of dementia
21. Cholinergic modulation of human P3 event-related potentials
22. Rational and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes
23. Mapping of event-related potentials (ERPs) to auditory and visual odd-ball paradigms in controls
24. The P300 wave of the human event related potential
25. Cognitive and biologic determinants of P300: An integrative review
26. Recommendations guiding physicians in biomedical research involving human subjects
27. Mini-Mental State: A practical method for grading the cognitive state of patients for clinician
28. The global deterioration scale for assessment of primary degenerative dementia
29. A new rating scale for dementia syndromes
30. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
31. Clinical diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
32. The definition, identification and reliability of measurement of the P300 component of the eventrelated brain potential
33. P3 recordings in patients with bilateral temporal lobe lesions
34. Delayed P3 event-related potentials (ERPs) in thalamic hemorrhage
35. Significance probability mapping: An aid in the topographic analysis of brain electrical activity
36. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
37. Behavioral symptoms in Alzheimer's disease: Improvement with donepezil
38. Wave form and neural mechanism of the decision P350 elicited without prestimulus CNV or readiness potential in random sequences of near threshold auditory clicks and finger stimuli
39. A triarchic model of P300 amplitude
40. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia